Precision biosciences inc stock.

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2023 and provide a business update on May 9, 2023.About …This Stock Purchase Agreement (this “Agreement”) is entered into as of June 14, 2022 (the “Execution Date”), by and between Precision BioSciences, Inc., a corporation organized and existing under the laws of Delaware, with its principal business office located at 302 E Pettigrew St - Dibrell Whse Suite A-100, Durham, North Carolina ...Yu: Precision BioSciences: Current Employment, Current equity holder in publicly-traded company. Heery: Precision BioSciences: Current equity holder in publicly-traded company, Ended employment in the past 24 months; Arcellx: Current Employment, Current holder of stock options in a privately-held company.WebEarnings for Precision BioSciences are expected to grow in the coming year, from ($0.29) to ($0.21) per share. Precision BioSciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 14th, 2024 based off prior year's report dates. Read More.Precision Biosciences Inc (NASDAQ:DTIL)’s traded shares stood at 0.64 million during the latest session, with the company’s beta value hitting 1.50. At the last check today, the stock’s price was $0.41, to imply a decrease of -3.21% or -$0.01 in intraday trading. The DTIL share’s 52-week ...

Corporate Profile Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary …About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control …DURHAM, N.C.--(BUSINESS WIRE)--May 31, 2023-- Precision BioSciences, Inc. ... risks related to ownership of our common stock, including fluctuations in our stock price, and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, ...Web

Precision BioSciences Inc. is based in Durham, North Carolina. Stock Name, Country, Market Cap, PE Ratio. Amgen (AMGN), United States, $142.010B, 14.72. Bristol ...Jun 20, 2023 · Precision Biosciences Inc (US:DTIL) has 116 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 42,897,221 shares.

Get the latest Pressure Biosciences Inc (PBIO) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.WebOverall, Precision BioSciences Inc stock has a Value Grade of C, Growth Grade of C, Quality Grade of D, Momentum Grade of F Earnings Estimate Revisions Grade of C. Whether or not you should buy Precision BioSciences Inc stock will ultimately depend on your individual goals, risk tolerance and allocation. AAII can help you figure …Precision BioSciences Annual Revenue Estimates (Precision BioSciences) The company’s market cap is about $152M, so that would be a roughly 0.3x forward price-to-sales. Considering the industry ...2015. 122. Yujiro Hata. https://www.ideayabio.com. IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company’s lead product candidates include IDE397, a …Web

Exhibit 3.1. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION. OF. PRECISION BIOSCIENCES, INC. The name of the corporation is Precision BioSciences, Inc., ...

Founders Derek Jantz, Jeff Smith, Matthew Kane. Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Precision BioSciences, Inc. Stock Symbol NASDAQ:DTIL. Company Type For Profit. Contact Email [email protected]. Phone Number +1 919 314-5512. Precision …Web

Precision Biosciences says it has cash to run through Q1 2025 Apr. 18, 2023 9:09 AM ET Precision BioSciences, Inc. (DTIL) By: Jonathan Block , SA News Editor Juanmonino/E+ via Getty ImagesWebNov 7, 2023 · DURHAM, N.C., November 07, 2023 -- ( BUSINESS WIRE )--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in ... Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic ... Weighted average shares of common stock ...DURHAM, N.C.--(BUSINESS WIRE)--Jun. 27, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced the closing of an underwritten offering of 35,971,224 shares of its …Information on stock, financials, earnings, subsidiaries, investors, and executives for Precision BioSciences. Use the PitchBook Platform to explore the full profile. ... Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, A. Biotechnology. Durham, NC. 115 As of 2023 00000 ...WebDURHAM, N.C.--(BUSINESS WIRE)--Jul. 27, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic CAR T therapies, today announced that it has received final meeting minutes from its recent Type B End of Phase 1 meeting with the U.S. Food and Drug Administration (FDA) for its lead ...Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other ...

Corporate Profile Precision BioSciences, Inc. (Nasdaq: DTIL), is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary …Investor Contact. Tim Kelly. (857) 702-9452. Email: [email protected]. The Investor Relations website contains information about Praxis Precision Medicines, Inc.'s business for stockholders, potential investors, and financial analysts.About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform.Precision BioSciences, Inc. announced that it has received final meeting minutes from its recent Type B End of Phase 1 meeting with the U.S. Food and Drug Administration for its lead investigational...On Monday, Precision Biosciences Inc [NASDAQ:DTIL] saw its stock fall -6.04% to $0.40. On the same session, the stock had its day’s lowest price of $0.3921, but rose to a high of $0.4395. Over the last five days, the stock has gained 29.21%. Precision Biosciences Inc shares have fallen nearly -66.39% since the year began.Aug 15, 2023 · About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Find the latest Precision BioSciences, Inc. (PBS.F) stock quote, history, news and other vital information to help you with your stock trading and investing.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. ... The increase in weighted average shares of common …

Precision BioSciences, Inc is a clinical-stage gene editing company. It is developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in …Stock Price Forecast The 4 analysts offering 12-month price forecasts for Precision BioSciences Inc have a median target of 2.75, with a high estimate of 3.00 and a low estimate of 2.00.Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing and ex vivo allogeneic ... Weighted average shares of common stock ...View All The Investor Relations website contains information about Precision BioSciences's business for stockholders, potential investors, and financial analysts.Aug 15, 2023 · About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Nov 24, 2023 · When you look at Precision BioSciences Inc’s price-to-sales ratio at 0.93 compared to the industry median at 6.93, this company has a lower price relative to revenue compared to its peers. This could make Precision BioSciences Inc’s stock more attractive for value investors.

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board ...

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that, on November 21, 2023, the Compensation Committee of Precision’s Board ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene ed ... Weighted average shares of common stock ...If you are looking for stocks with good return, Precision Biosciences Inc stock can be a bad, high-risk 1-year investment option. Precision Biosciences Inc real time quote is equal to 0.363 USD at 2023-12-03, but your current investment may be devalued in the future. ...WebNovember 7, 2023 at 4:54 AM · 3 min read. Revenues for Q3 2023 were $13.1 million, a significant increase from $7.4 million in Q3 2022. Net loss for the quarter was $8.1 million, or $ (0.07) per ...Nov 24, 2023 · When you look at Precision BioSciences Inc’s price-to-sales ratio at 0.93 compared to the industry median at 6.93, this company has a lower price relative to revenue compared to its peers. This could make Precision BioSciences Inc’s stock more attractive for value investors. Nov 24, 2023 · When you look at Precision BioSciences Inc’s price-to-sales ratio at 0.93 compared to the industry median at 6.93, this company has a lower price relative to revenue compared to its peers. This could make Precision BioSciences Inc’s stock more attractive for value investors. The inducement award consists of an option to purchase (“stock option”) 160,000 shares of Precision’s common stock, par value $0.000005 (the “Common Stock”), which was granted to an ...WebAnalysts Just Published A Bright New Outlook For Precision BioSciences, Inc.'s (NASDAQ:DTIL) Simply Wall St. August 6, 2023 at 5:03 AM · 2 min read. Celebrations may be in order for Precision ...Nov 9, 2023 · On November 7, 2023, Precision BioSciences Inc (DYAI) stock showed promising performances based on the information provided. According to data from CNN Money, the four analysts offering 12-month price forecasts for DYAI had a median target of $3.00, with a high estimate of $4.00 and a low estimate of $2.00.

Precision Biosciences has been on a roll with positive updates in both their CAR T-Cell and gene editing pipelines. Find out why I rate DTIL stock a Buy.WebPrometheus Biosciences, Inc. is a clinical-stage biotechnology company. The Company discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample …When you look at Precision BioSciences Inc’s price-to-sales ratio at 0.93 compared to the industry median at 6.93, this company has a lower price relative to revenue compared to its peers. This could make Precision BioSciences Inc’s stock more attractive for value investors.The inducement award consists of an option to purchase (“stock option”) 160,000 shares of Precision’s common stock, par value $0.000005 (the “Common …Instagram:https://instagram. worth of bicentennial quarterfirst solar sharesnasdaq vodlucid midnight dream edition Get the latest Precision BioSciences Inc (DTIL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and … svol stock dividendfuturistic mercedes benz We credit much of our successes not only to our technical know-how, but our commitment to our team and our culture. Precision BioSciences utilizes its proprietary ARCUS Genome Editing method to overcome cancers, cure genetic diseases, and enable development of safer food.Get the latest stock price for Precision BioSciences Inc. (DTIL:US), plus the latest news, recent trades, charting, insider activity, and analyst ratings. rumble app stock SOUTH SAN FRANCISCO, Calif., Dec. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company …View All The Investor Relations website contains information about Precision BioSciences's business for stockholders, potential investors, and financial analysts.